title: Effects of diazepam on nociception in rats.
abstract: Acute i.p. injection of diazepam (1 mg/kg) resulted in a moderate increase in the tail-flick latency in rats. Tolerance to this diazepam effect developed after 10 days of diazepam treatment (1 mg kg-1 day-1). The benzodiazepine antagonist Ro 15-3505 only partially reversed the effect of diazepam on nociception. Naloxone (5 mg/kg i.p.) failed to affect the effect of diazepam on nociception, while the kappa antagonist MR 2266 fully antagonized the diazepam-induced increase of the tail-flick latency. Diazepam injected intracerebroventricularly (1, 5, 20 micrograms/rat) did not alter basal nociceptive threshold, however, diazepam injected intrathecally (20 micrograms/rat) prolonged the tail-flick latency. Furthermore, intracerebroventricular injection of muscimol partially antagonized the i.p. diazepam-induced increase of the tail-flick latency. These results suggest that benzodiazepine receptor sites are partially involved in the effect of diazepam on nociception and indicate that an indirect kappa-opioid-receptor-mediated mechanism may be involved. The anatomical site of diazepam action on tail-flick latency seems to be at the spinal level. Descending axons to the spinal cord from brain areas reached by intracerebroventricular injection of muscimol seem to modulate the effect of diazepam effect on nociception.
authors.affiliation: Department of Pharmacology, School of Medicine, University of Milano, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Zambotti
authors.forename: N
authors.initials: N
authors.lastname: Zonta
authors.forename: R
authors.initials: R
authors.lastname: Tammiso
authors.forename: F
authors.initials: F
authors.lastname: Conci
authors.forename: B
authors.initials: B
authors.lastname: Hafner
authors.forename: L
authors.initials: L
authors.lastname: Zecca
authors.forename: P
authors.initials: P
authors.lastname: Ferrario
authors.forename: P
authors.initials: P
authors.lastname: Mantegazza
mesh_terms: D000818:Animals; D001569:Benzodiazepines / Q000037:antagonists & inhibitors; D001570:Benzodiazepinones / Q000494:pharmacology; D001575:Benzomorphans / Q000494:pharmacology; D002707:Chlordiazepoxide / Q000494:pharmacology; D003292:Convulsants / Q000494:pharmacology; D003975:Diazepam / Q000008:administration & dosage / Q000494:pharmacology*; D004347:Drug Interactions; D007274:Injections, Intraperitoneal; D007276:Injections, Intraventricular; D007278:Injections, Spinal; D008297:Male; D008874:Midazolam / Q000008:administration & dosage / Q000494:pharmacology; D009118:Muscimol / Q000008:administration & dosage / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D009619:Nociceptors / Q000187:drug effects*; D010147:Pain Measurement / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors
chemical_list: D001570:Benzodiazepinones; D001575:Benzomorphans; D003292:Convulsants; D009292:Narcotic Antagonists; D001569:Benzodiazepines; D009118:Muscimol; D009270:Naloxone; C027247:MR 2266; D002707:Chlordiazepoxide; C040725:Ro 15-3505; D003975:Diazepam; D008874:Midazolam